Microhemodynamic consequences of tumor angiogenesis targeting using the tyrosine kinase inhibitor SU11248

被引：0
|
作者：
Czabanka, M.
Erber, R.
Vinci, M.
Ullrich, A.
Vajkoczy, P.
机构：
[1] Univ Heidelberg, Klinikum Mannheim, Dept Neurosurg, Mannheim, Germany
[2] Max Planck Inst Biochem, D-82152 Martinsried, Germany
来源：
JOURNAL OF VASCULAR RESEARCH | 2006年 / 43卷 / 06期
关键词：
D O I：
暂无
中图分类号：
Q4 [生理学];
学科分类号：
071003 ;
摘要：
引用
收藏
页码：564 / 564
页数：1
相关论文
共 50 条
  • [41] Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST).
    Fletcher, JA
    Heinrich, MC
    Morgan, JA
    George, S
    Desai, J
    Scheu, K
    Fletcher, CDM
    Baum, C
    Demetri, GD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 818S - 818S
  • [42] Pharmacodynamic case study of sunitinib/SU11248 in a gastrointestinal stromal tumor patient: Evidence toward a mechanism of effect.
    Seandel, M.
    Shia, J.
    Linkov, I.
    Maki, R. G.
    Antonescu, C.
    Dupont, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 526S - 526S
  • [43] INHIBITION OF ANGIOGENESIS BY ERBSTATIN, AN INHIBITOR OF TYROSINE KINASE
    OIKAWA, T
    ASHINO, H
    SHIMAMURA, M
    HASEGAWA, M
    MORITA, I
    MUROTA, S
    ISHIZUKA, M
    TAKEUCHI, T
    JOURNAL OF ANTIBIOTICS, 1993, 46 (05): : 785 - 790
  • [44] SU11248, a potent and selective inhibitor of the VEGF and PDGF receptors:: Preclinical pharmacokinetics in Sprague-Dawley rats and cynomolgus monkeys
    Haznedar, JÖ
    Yu, S
    Van Petten, M
    Wong, S
    Du, A
    Plise, E
    Vela, J
    Zhang, QL
    Sweeny, D
    Antonian, L
    Sukbuntherng, J
    DRUG METABOLISM REVIEWS, 2002, 34 : 138 - 138
  • [45] The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis
    Naumova, E
    Ubezio, P
    Garofalo, A
    Borsotti, P
    Cassis, L
    Riccardi, E
    Scanziani, E
    Eccles, SA
    Bani, MR
    Giavazzi, R
    CLINICAL CANCER RESEARCH, 2006, 12 (06) : 1839 - 1849
  • [46] Effect of SU11248, a class III receptor tyrosine kinase inhibitor, on GIST-T1 cells and enhancement of growth inhibition mediated by the inhibitors of P13-K/Akt/mTOR signaling.
    Ikezoe, T
    Yang, Y
    Bandobashi, K
    Taguchi, T
    Koeffler, HP
    Taguchi, H
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9043S - 9043S
  • [47] Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy
    Bronte, Giuseppe
    Bronte, Enrico
    Novo, Giuseppina
    Pernice, Gianfranco
    Lo Vullo, Francesca
    Musso, Emmanuela
    Bronte, Fabrizio
    Gulotta, Eliana
    Rizzo, Sergio
    Rolfo, Christian
    Silvestris, Nicola
    Bazan, Viviana
    Novo, Salvatore
    Russo, Antonio
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (02) : 253 - 267
  • [48] Quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction
    Barattè, S
    Sarati, S
    Frigerio, E
    James, CA
    Ye, C
    Zhang, Q
    JOURNAL OF CHROMATOGRAPHY A, 2004, 1024 (1-2) : 87 - 94
  • [49] TIVOZANIB VEGFR Tyrosine Kinase Inhibitor Angiogenesis Inhibitor Oncolytic
    Campas, C.
    Bolos, J.
    Castaner, R.
    DRUGS OF THE FUTURE, 2009, 34 (10) : 793 - 796
  • [50] Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2
    Shukla, Suneet
    Robey, Robert W.
    Bates, Susan E.
    Ambudkar, Suresh V.
    DRUG METABOLISM AND DISPOSITION, 2009, 37 (02) : 359 - 365
12345